Dignify is developing two products to treat bladder and bowel dysfunction associated with spinal cord injury, neurological diseases, diabetes and the elderly. Currently, many of these individuals require bladder catheterization for urination, and an invasive, time-consuming manual bowel program for defecation that is often performed by a caregiver. Dignify’s lead drug program, DTI-301, is a suppository that patients use as-needed for bowel evacuation. DTI-301 induces defecation within 5-10 minutes, with minimal absorption and systemic exposure. Our second drug program, DTI-117, is currently in development for on-demand emptying of both the bladder and bowel. DTI-117 is a small peptide that directly stimulates smooth muscle contraction in the bladder and bowel and produces voiding in less than 10 minutes. Additionally, the drug has a very short plasma half-life, is eliminated rapidly, and development is NIH-funded into clinical studies.

Anthony DiTonno, Dignify CEO, stated “The BIO Investor Forum provides a platform for discussions with institutional investors and strategic partners. As our two drug products are approaching clinical trials, we look forward to presenting Dignify’s novel approach to treating severe unmet medical needs for desperate patients in a multi-billion dollar market”.

About Dignify Therapeutics

Founded by a team of serial entrepreneurs who are internationally recognized scientists and clinicians, Dignify’s mission is to provide safe, effective, practical and convenient, “on-demand” pharmaceutical agents to treat bladder and bowel voiding dysfunctions. The company has been funded by RA Capital Management, Eshelman Ventures, the North Carolina Biotechnology Center, NIDDK, NINDS, NICHD, NIA, US Defense Department, and the One NC Small Business Program. Dignify is located at the First Flight Venture Center in Research Triangle Park, North Carolina. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

PRESS CONTACT

Dignify Therapeutics
Anthony DiTonno, CEO
2 Davis Drive
Research Triangle Park, NC 27709
ditonno@dignifytherapeutics.com
dignifytherapeutics.com

The post Dignify Therapeutics to Participate in the BIO Investor Forum, October 2024 appeared first on Dignify Therapeutics.

Mr. Palefsky has a broad range of experience as a Board Member and Advisor in the healthcare and biomedical industries, having served these industries as an Entrepreneur, CEO, Board Chair, Director and Investor. He has served on the Boards of more than 30 companies. Businesses in which Mr. Palefsky played a seminal role have achieved numerous product launches, financings, IPOs, M&A transactions and significant value creation. Mr. Palefsky also keeps an active schedule focused on governance and philanthropy in the arts and culture sectors.

Dr. Kurtz is a physician with over 40 years of experience in healthcare, holding Senior Executive positions in the pharmaceutical, contract research, post-acute care, and medical diagnostic verticals.  Dr. Kurtz has been the CEO of both public and private companies and has founded three companies, including Medidata Systems and Worldwide Clinical Trials, which has created over 8 billion dollars of value to investors upon their respective sales. He has served on multiple Boards of both public and private healthcare companies and has published over forty articles and books related to various healthcare-related topics.

Anthony DiTonno, Dignify’s CEO and Executive Chairman remarked “The addition of Howard and Neil to our board of directors is a major step forward for Dignify. I have worked with both these gentlemen before, and I look forward to having their keen sense of strategic focus and financial acumen at the table.”.

About Dignify Therapeutics

Founded by a team of serial entrepreneurs who are internationally recognized scientists and clinicians, Dignify’s mission is to provide safe, effective, practical and convenient, “on-demand” pharmaceutical agents to treat bladder and bowel voiding dysfunctions. The company has been funded by RA Capital Management, Eshelman Ventures, the North Carolina Biotechnology Center, NIDDK, NINDS, NICHD, NIA, US Defense Department, and the One NC Small Business Program. Dignify is located at the First Flight Venture Center in Research Triangle Park, North Carolina.

PRESS CONTACT

Dignify Therapeutics
Anthony DiTonno, CEO
2 Davis Drive
Research Triangle Park, NC 27709
ditonno@dignifytherapeutics.com
dignifytherapeutics.com

The post Dignify Therapeutics welcomes leading healthcare entrepreneurs Howard Palefsky and Neil Kurtz, MD to its Board of Directors appeared first on Dignify Therapeutics.